Home › Compare › AGLE vs MCD

AGLE vs MCD: Dividend Comparison 2026

AGLE yields 16.65% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $18.4K in total portfolio value· pulled ahead in Year 10
10 years
AGLE
AGLE
● Live price
16.65%
Share price
$12.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.3K
Annual income
$4,631.17
Full AGLE calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — AGLE vs MCD

📍 MCD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGLEMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGLE + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AGLE pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGLE
Annual income on $10K today (after 15% tax)
$1,415.49/yr
After 10yr DRIP, annual income (after tax)
$3,936.49/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, MCD beats the other by $18,021.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGLE + MCD for your $10,000?

AGLE: 50%MCD: 50%
100% MCD50/50100% AGLE
Portfolio after 10yr
$68.5K
Annual income
$15,232.28/yr
Blended yield
22.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

AGLE
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
3/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGLE buys
0
MCD buys
0
No recent congressional trades found for AGLE or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGLEMCD
Forward yield16.65% ✓2.34%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$59.3K$77.7K ✓
Annual income after 10y$4,631.17$25,833.37 ✓
Total dividends collected$30.5K$57.7K ✓
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy

Year-by-year: AGLE vs MCD ($10,000, DRIP)

YearAGLE PortfolioAGLE Income/yrMCD PortfolioMCD Income/yrGap
1$12,365$1,665.28$10,812$332.41+$1.6K → AGLE
2$15,155$1,924.45$11,819$488.02+$3.3K → AGLE
3$18,421$2,204.37$13,111$724.37+$5.3K → AGLE
4$22,214$2,504.02$14,832$1,091.05+$7.4K → AGLE
5$26,591$2,822.14$17,219$1,675.85+$9.4K → AGLE
6$31,610$3,157.22$20,688$2,641.85+$10.9K → AGLE
7$37,330$3,507.56$25,990$4,309.70+$11.3K → AGLE
8$43,814$3,871.31$34,590$7,351.77+$9.2K → AGLE
9$51,128$4,246.52$49,535$13,285.25+$1.6K → AGLE
10← crossover$59,338$4,631.17$77,746$25,833.37$18.4K → MCD

AGLE vs MCD: Complete Analysis 2026

AGLE — Stock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Full AGLE Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this AGLE vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGLE vs SCHDAGLE vs JEPIAGLE vs OAGLE vs KOAGLE vs MAINAGLE vs YUMAGLE vs QSRAGLE vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.